BRCA1 and breast carcinoma: While a meta-analysis of 18 studies suggested similar response rates for PARPi with germline and somatic BRCA1/2 mutations [91], less is known about the role of somatic mutations of BRCA1/2 in predicting response to PARPi in breast cancer.